[镥]-PSMA-617放射性核素疗法治疗转移性去势抵抗性前列腺癌患者 - Suppr

Suppr

超能文献

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.

作者信息

Derlin Thorsten, Schmuck Sebastian

机构信息

Department of Nuclear Medicine, Hannover Medical School, D-30625 Hannover, Germany.

出版信息

Lancet Oncol. 2018 Aug;19(8):e372. doi: 10.1016/S1470-2045(18)30488-1.

DOI:10.1016/S1470-2045(18)30488-1

PMID:30102222

Abstract

摘要

相似文献

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.[镥]-PSMA-617放射性核素疗法治疗转移性去势抵抗性前列腺癌患者

Lancet Oncol. 2018 Aug;19(8):e372. doi: 10.1016/S1470-2045(18)30488-1.

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer.[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者。

Lancet Oncol. 2018 Aug;19(8):e371. doi: 10.1016/S1470-2045(18)30410-8.

[Lu]-PSMA-617 radionuclide therapy in patients with metastatic castration-resistant prostate cancer - Author's reply.[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者——作者回复

Lancet Oncol. 2018 Aug;19(8):e373. doi: 10.1016/S1470-2045(18)30534-5.

Re: [Lu]-PSMA-617 Radionuclide Treatment in Patients with Metastatic Castration-resistant Prostate Cancer (LuPSMA Trial): A Single-centre, Single-arm, Phase 2 Study.回复：[镥]-PSMA-617放射性核素治疗转移性去势抵抗性前列腺癌患者（镥PSMA试验）：一项单中心、单臂、2期研究。

Eur Urol. 2019 Mar;75(3):536-537. doi: 10.1016/j.eururo.2018.11.005. Epub 2018 Nov 15.

[Lu]PSMA-617 radionuclide therapy shows promise.[卢]PSMA - 617放射性核素疗法显示出前景。

Nat Rev Urol. 2018 Aug;15(8):468. doi: 10.1038/s41585-018-0029-6.

Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer.Bi-PSMA-617靶向α放射性核素疗法治疗转移性去势抵抗性前列腺癌

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1099-1100. doi: 10.1007/s00259-017-3657-9. Epub 2017 Mar 2.

PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.使用¹⁷⁷Lu标记的PSMA-617对转移性去势抵抗性前列腺癌进行PSMA靶向放射性核素治疗。

J Nucl Med. 2016 Aug;57(8):1170-6. doi: 10.2967/jnumed.115.171397. Epub 2016 Mar 16.

[Lu]-PSMA-617 for targeted prostate cancer treatment: a magic bullet?用于靶向治疗前列腺癌的[镥]-PSMA-617：神奇子弹？

Lancet Oncol. 2018 Jun;19(6):725-726. doi: 10.1016/S1470-2045(18)30268-7. Epub 2018 May 8.

Additional Local Therapy for Liver Metastases in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Systemic PSMA-Targeted Therapy.转移性去势抵抗性前列腺癌患者接受系统 PSMA 靶向治疗时，肝脏转移灶的附加局部治疗。

J Nucl Med. 2020 May;61(5):723-728. doi: 10.2967/jnumed.119.233429. Epub 2019 Oct 10.

[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma.[44Sc]Sc-PSMA-617 示踪剂在转移性去势抵抗性前列腺癌患者中的生物分布和剂量学研究。

Clin Nucl Med. 2018 May;43(5):323-330. doi: 10.1097/RLU.0000000000002003.

引用本文的文献

Ultrasmall Gold Nanoparticles Radiolabeled with Iodine-125 as Potential New Radiopharmaceutical.超小尺寸的金纳米粒子经碘-125 放射性标记后，有望成为新型放射性药物。

ACS Appl Bio Mater. 2024 Feb 19;7(2):1240-1249. doi: 10.1021/acsabm.3c01158. Epub 2024 Feb 7.

Correlation of an Index-Lesion-Based SPECT Dosimetry Method with Mean Tumor Dose and Clinical Outcome after Lu-PSMA-617 Radioligand Therapy.基于指数病变的SPECT剂量测定法与Lu-PSMA-617放射性配体治疗后平均肿瘤剂量及临床结果的相关性

Diagnostics (Basel). 2021 Mar 3;11(3):428. doi: 10.3390/diagnostics11030428.

Radiopharmaceutical therapy in cancer: clinical advances and challenges.放射性药物治疗癌症：临床进展与挑战。

Nat Rev Drug Discov. 2020 Sep;19(9):589-608. doi: 10.1038/s41573-020-0073-9. Epub 2020 Jul 29.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验